一种免疫组合物及其应用

By combining the TLR2 agonist SUP3 with the immune checkpoint inhibitor PD-L1 and the cytokine Flt3L, the immune system is activated, and the maturation of antigen-presenting cells (DCs) is promoted. This addresses the shortcomings of existing technologies in the application of TLR2 agonists in tumor treatment, and achieves effective tumor suppression and immune memory response.

CN117771362BActive Publication Date: 2026-07-17TSINGHUA UNIVERSITY
View PDF 4 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
TSINGHUA UNIVERSITY
Filing Date
2022-12-05
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

There are no existing reports on using the TLR2 agonist SUP3 in combination with other therapeutic agents to achieve immunotherapy for tumors.

Method used

An immune composition is provided, comprising the TLR2 agonist SUP3 and an immune checkpoint inhibitor, such as a PD-L1 antibody, and the cytokine Flt3L, which, when used in combination in different proportions and via administration, activate the immune system and promote the maturation of antigen-presenting cells (DCs) and immune responses.

Benefits of technology

It significantly enhances the therapeutic effect on tumors, inhibits tumor growth in situ and distant metastasis, and induces immune memory response. It has a wide range of therapeutic effects when applied to solid tumors and hematological malignancies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117771362B_ABST
    Figure CN117771362B_ABST
Patent Text Reader

Abstract

本发明公开了一种免疫组合物和一种TLR2激动剂与治疗剂联用在制备预防和 / 或治疗肿瘤的药物中的应用，所述治疗剂为免疫检查点抑制剂和 / 或细胞因子。具体来讲，本发明采用新型TLR2激动剂SUP3联合免疫检查点抑制剂PD‑L1和造血干细胞生长因子Flt3L来实现对肿瘤的免疫治疗，其能够抑制肿瘤原位组织的增长以及肿瘤的远端转移；诱导机体产生免疫记忆反应，且维持较长时间的免疫记忆；促进DC成熟，表达CD40、CD80等共刺激分子，且促进DC表面高表达免疫抑制分子PD‑L1，此免疫组合疗法可应用于各种实体瘤和血液瘤，应用范围广，效果良好。
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Use of a TLR7 agonist in combination with a tyrosine kinase inhibitor in the preparation of an anti-tumor drug

    CN105311032B

  • Treatment of cancer using tlr9 agonists and checkpoint inhibitors

    CN115040532A

  • Combination of TOLL-like receptor stimulating agent and immune effector cell

    CN108853144A

  • Methods for treatment using phthalocyanine dye-targeting molecule conjugates

    US20220296712A1